YU47699A - Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonists - Google Patents

Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonists

Info

Publication number
YU47699A
YU47699A YU47699A YU47699A YU47699A YU 47699 A YU47699 A YU 47699A YU 47699 A YU47699 A YU 47699A YU 47699 A YU47699 A YU 47699A YU 47699 A YU47699 A YU 47699A
Authority
YU
Yugoslavia
Prior art keywords
carboxylic acid
amino acids
quinoline
antagonists
excitatory amino
Prior art date
Application number
YU47699A
Other languages
Serbo-Croatian (sh)
Inventor
Fabio Romano Di
Barbara Bertani
Giuseppe Alvaro
Wellcome S.p.A. Glaxo
Original Assignee
Glaxo Wellcome S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome S.P.A. filed Critical Glaxo Wellcome S.P.A.
Publication of YU47699A publication Critical patent/YU47699A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

The (+) enantiomer of E 4-(4-Acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro quinoline 2-carboxylic acid and salt thereof which are antagonist of excitatory amino acids, to processes for their preparation, to pharmaceutical compositions containing them, and to their use in medicine.
YU47699A 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonists YU47699A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound

Publications (1)

Publication Number Publication Date
YU47699A true YU47699A (en) 2001-12-26

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
YU47699A YU47699A (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonists

Country Status (20)

Country Link
EP (1) EP0971896A1 (en)
JP (1) JP2001518901A (en)
KR (1) KR20010005567A (en)
CN (1) CN1257482A (en)
AP (1) AP9901659A0 (en)
AU (1) AU731394B2 (en)
BR (1) BR9808424A (en)
CA (1) CA2284710A1 (en)
EA (1) EA199900755A1 (en)
GB (1) GB9706294D0 (en)
HU (1) HUP0001661A3 (en)
ID (1) ID24306A (en)
IL (1) IL131919A0 (en)
IS (1) IS5186A (en)
NO (1) NO994679L (en)
NZ (1) NZ337793A (en)
PL (1) PL335865A1 (en)
TR (1) TR199902315T2 (en)
WO (1) WO1998042673A1 (en)
YU (1) YU47699A (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (en) 2001-07-05 2006-08-03 Grünenthal GmbH Substituted γ-lactone compounds
DE10137487A1 (en) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituted 5,6,6a, 11b-tetrahydro-7-oxa-6-aza-benzo [c] fluorene-6-carboxylic acid derivatives
DE10306202A1 (en) 2003-02-13 2004-08-26 Grünenthal GmbH 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist
JP4360891B2 (en) 2003-12-09 2009-11-11 アルパイン株式会社 Electronic device having broadcast receiving function and display method of electronic program guide in the device
KR101136183B1 (en) 2005-07-22 2012-04-17 모찌다 세이야쿠 가부시끼가이샤 Novel heterocyclidene acetamide derivative
RU2451014C2 (en) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Novel heterocyclidene acetamide derivative
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP7305560B2 (en) 2017-06-12 2023-07-10 グリテック， エルエルシー Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
TR199800531T1 (en) * 1995-09-29 1998-06-22 Glaxo Wellcome Spa Tetrahydroquinolines as NMDA antagonists.
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
GB9706294D0 (en) 1997-05-14
ID24306A (en) 2000-07-13
PL335865A1 (en) 2000-05-22
TR199902315T2 (en) 2000-05-22
AP9901659A0 (en) 1999-09-30
HUP0001661A3 (en) 2001-12-28
NZ337793A (en) 2001-02-23
JP2001518901A (en) 2001-10-16
NO994679L (en) 1999-11-24
WO1998042673A1 (en) 1998-10-01
IL131919A0 (en) 2001-03-19
AU7209498A (en) 1998-10-20
CN1257482A (en) 2000-06-21
AU731394B2 (en) 2001-03-29
EP0971896A1 (en) 2000-01-19
KR20010005567A (en) 2001-01-15
BR9808424A (en) 2000-05-23
EA199900755A1 (en) 2000-08-28
NO994679D0 (en) 1999-09-24
HUP0001661A2 (en) 2000-09-28
CA2284710A1 (en) 1998-10-01
IS5186A (en) 1999-09-17

Similar Documents

Publication Publication Date Title
WO2003020698A3 (en) Protein tyrosine kinase inhibitors
BR0315547A (en) Quinoline derivatives as crth2 antagonists
DE60037020D1 (en) Anilinochinazoline als protein-tyrosin-kinasehemmer
TR200002015T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
HUP0004490A2 (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threoning kinase inhibitors and pharmaceutical compositions containing them
CA2473991A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
MY115638A (en) N-substituted heterocyclic derivatives, their preparation and pharmaceutical compositions containing them
IL90435A0 (en) 4-(quinolin-2-yl-methoxy)phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them
HUP0105133A3 (en) Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
CA2274825A1 (en) Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase
TR199801861T2 (en) Pharmaceutically useful compositions.
CA2327029A1 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
EP1179533A3 (en) Salt of naphthyridine carboxylic acid derivative
TR199900336T2 (en) Tetrahydroquinoline derivatives as EAA antagonists.
MX9801987A (en) Amino acid derivatives, the preparation and use thereof as endothelin antagonists.
YU47699A (en) Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonists
TR199800531T1 (en) Tetrahydroquinolines as NMDA antagonists.
HUP0301080A3 (en) Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives, process for their preparation and pharmaceutical compositions containing them
TR200103457T2 (en) 4-Phenyl-Pyrimidine Derivatives.
CY1106105T1 (en) MEGLUMINE SALT OF A SPECIFIC QUINOLINECARBOXYLIC ACID ACTIVE AT NMDA RECEPTORS
ATE285772T1 (en) USE OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES AS AMPA ANTAGONISTS
TR199901380A2 (en) Di-ya da triazo-spiro$4.5] dean t�revleri
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
BG105618A (en) Beta-amido and beta-sulphonamide derivatives of carboxylic acids, method for preparation and application as endothelin-receptor antagonists
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS